NeuroBo to Participate in Investor Conferences in December
BOSTON, Dec. 1, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, Marshall H. Woodworth, Acting Chief Financial Officer and Robert Homolka, Senior Vice President of Clinical Operations, will present a company overview, including updates on the company’s promising cardiometabolic assets, DA-1241, in development as a treatment for NASH and DA-1726, in development for the treatment of obesity, at the following investor conferences in December:
Related news for (NRBO)
- NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia – Reflecting the Company’s Focus on Cardiometabolic Diseases
- neurobo pharmaceuticals announces positive top-line data from the sad part 1 of its phase 1 clinical trial evaluating da-1726 for the treatment of obesity
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
- NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement